MYCN and cancer: Determination of a common set of N-MYC–WDR5 cobound sites across CHP-134 and IMR-32 cell lines reveals that most of these common binding sites overlap with the conserved set of WDR5-bound sites (Fig. 4G), suggesting that N-MYC—or any other MYC family member for that matter—is most likely found with WDR5 at these regions regardless of cancer context.